Convalescent plasma in oncohematological patients

Affiliations

¹ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
² Division of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.
³ Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, USA.
⁵ Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, Maryland, USA.

Comment

Daniele Focosi et al. Hematol Oncol. 2023 Feb.

. 2023 Feb;41(1):208-209.

doi: 10.1002/hon.3069. Epub 2022 Aug 27.

¹ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
² Division of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.
³ Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, USA.
⁵ Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, Maryland, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; convalescent plasma; oncohematology.

Conflict of interest statement

We have no relevant conflict of interest related to this manuscript.

Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.
Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi MV, Guidetti A, Marchetti M, Massaia M, Arcaini L, Krampera M, Mohamed S, Gherlinzoni F, Mecucci C, Gentile M, Romano I, Venditti A, Ruggeri M, Ferrero D, Coviello E, Fabbri E, Corradini P, Passamonti F. Lanza F, et al. Hematol Oncol. 2022 Dec;40(5):857-863. doi: 10.1002/hon.3060. Epub 2022 Aug 14. Hematol Oncol. 2022. PMID: 35932208 Free PMC article.

1. Lanza F, Monaco F, Ciceri F, et al. Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitannt hematological malignancies: an Italian retrospective study. Hematol Oncol. 2022. Online ahead of print. - PMC - PubMed
1. Focosi D, Casadevall A. Pathogen reduction technologies need to evaluate Fc‐mediated antibody functions. Transfusion. 2022;62(8):1680‐1681. 10.1111/trf.16995 - DOI - PubMed
1. Senefeld JW, Franchini M, Mengoli C, et al. COVID‐19 convalescent plasma for the treatment of immunocompromised patients: a systematic review. medRxiv. 2022. 10.1101/2022.08.03.22278359 - DOI - PMC - PubMed
1. US Food and Drug Administration (FDA) . Clinical Memorandum Re: EUA 26382. Product: COVID‐19 Convalescent Plasma. Issued on 27 December 2021. https://www.fda.gov/media/141477/download
1. IDSA Guidelines on the Treatment and Management of Patients with COVID‐19. Accessed February 9, 2022. https://www.idsociety.org/practice‐guideline/covid‐19‐guideline‐treatmen...